DRAGARWQDr Agarwals Eye Hospital Limited
Healthcare · Medical Care Facilities · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Dr. Agarwal's Eye Hospital Limited engages in the provision of eye care and related services in India, Ghana, Uganda, Kenya, Madagascar, Tanzania, Rwanda, Zambia, Mozambique, and Mauritius. The company, through its hospitals, offers services in the areas of cataract, glaucoma, laser correction, cornea and refractive, retina, squint, corneal ulcer, fungal keratitis, diabetic retinopathy, retinal detachment, nystagmus, ptosis, conjunctivitis, retinopathy prematurity, macular hole and edema, cornea transplantation, behcets, computer vision syndrome, hypertensive retinopathy, black fungus, traumatic cataract, keratoconus, uveitis, pterygium, blepharitis, posterior subcapsular cataract, rosette cataract, and congenital glaucoma. Dr. Agarwal's Eye Hospital Limited was founded in 1957 and is based in Chennai, India. Dr. Agarwal's Eye Hospital Limited operates as a subsidiary of Dr. Agarwal's Health Care Limited.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on DRAGARWQ — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 22.3% YoY
- • Profit growth: 31.8% YoY
- • ROE: 20.2%
- • RSI: 52
- • Price vs EMA21: above
- • Price vs SMA50: above
Bull case
- • Revenue growth: 22.3% YoY
- • Profit growth: 31.8% YoY
- • ROE: 20.2%
- • RSI: 52
Bear case
- • Dividend yield: 0.00%
- • MACD: bearish
- • Volume: 0.8x 20-day average
- • 1-month return: -2.1%
Key risks
- • Dividend yield: 0.00%
- • MACD: bearish
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹143.78). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.